imidafenacin: Clinical Trials

8 trials of imidafenacin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed. 3 Phase 3, 2 Phase 4, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Completed 3
Phase 42Completed 2
Phase 21Completed 1

Follow imidafenacin: new trials by email Literature Review of imidafenacin trials Research Report on imidafenacin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
mirabegron, solifenacin, darifenacin - Overactive Bladder (OAB)
CompletedAstellas Pharma Singapore Pte. Ltd.55892018-07-202024-10-16
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
mirabegron, solifenacin, darifenacin - Overactive Bladder (OAB)
CompletedAstellas Pharma Singapore Pte. Ltd.8052018-07-192020-04-22
Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.
Uritos®, Urotol® - Overactive Bladder
Phase 3CompletedR-Pharm3002016-07-182019-05-21
Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
Mirabegron tablet, Solifenacin tablet, Propiverine tablet - Overactive Bladder (OAB)
Phase 4CompletedAstellas Pharma Inc6492014-10-282024-10-31
Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder
Imidafenacin, Fesoterodine - Overactive Bladder
Phase 4CompletedLG Life Sciences2072010-12-012012-04-16
Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder
imidafenacin, KRP-197/ONO-8025 - Overactive Bladder
Phase 3CompletedOno Pharmaceutical Co., Ltd.4352007-08-012012-06-13
Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan
ONO-8025 (KRP-197) - Overactive Bladder
Phase 3CompletedOno Pharmaceutical Co., Ltd.7502003-10-012012-10-11
Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan
ONO-8025 (KRP-197) - Overactive Bladder
Phase 2CompletedOno Pharmaceutical Co., Ltd.4002001-10-012012-10-12

Conditions studied

Urinary Bladder, Overactive (8)  ·  Urinary Incontinence (1)  ·  Urinary Incontinence, Urge (1)

Sponsors

Ono Pharmaceutical Co., Ltd. (3)  ·  Astellas Pharma Singapore Pte. Ltd. (2)  ·  Astellas Pharma Inc (1)  ·  LG Life Sciences (1)  ·  R-Pharm (1)

Countries

South Korea (3)  ·  Japan (2)  ·  Australia (1)  ·  Russia (1)  ·  Taiwan (1)

Top investigators

Project Leader, Development Planning (2)  ·  Mikhail Samsonov (1)  ·  Toshihiko Konomi (1)  ·  Yoshifumi Hirahara (1)

Results publications

PMID 37148497, PMID 37160401, PMID 38430402